clindamycin


Also found in: Dictionary, Wikipedia.
Related to clindamycin: metronidazole, Clindamycin phosphate

clindamycin

 [klin″dah-mi´sin]
1. a semisynthetic antibiotic that is a derivative of lincomycin; used to treat gram-positive penicillin-resistant infections.
2. a semisynthetic derivative of lincomycin used systemically, topically, and vaginally as an antibacterial, primarily against gram-positive bacteria; used also as the hydrochloride and phosphate salts and as the hydrochloride salt of the ester of clindamycin and palmitic acid (clindamycin palmitate hydrochloride).

clindamycin

/clin·da·my·cin/ (klin″dah-mi´sin) a semisynthetic derivative of lincomycin used systemically, topically, and vaginally as an antibacterial, primarily against gram-positive bacteria; used also as the hydrochloride and phosphate salts and as the hydrochloride salt of the ester of clindamycin and palmitic acid.

clindamycin

(klĭn′də-mī′sĭn)
n.
A semisynthetic antibiotic, C18H33ClN2O5S, derived from lincomycin and active against gram-positive bacteria.

clindamycin

Infectious disease An antibiotic combined with pyrimethamine to treat and prevent toxoplasmosis, PCP and, topically, for acne vulgaris Adverse effects Diarrhea, dysgeusia. See AIDS.

clindamycin

An antibiotic drug that penetrates well into bone to treat OSTEOMYELITIS. The drug is on the WHO official list. Brand names are Dalacin C and, for external use, Dalacin T.

clindamycin

macrolide; antibiotic agent effective against Gram-positive cocci, penicillin-resistant staphylococci (e.g. meticillin-resistant Staphylococcus aureus [MRSA]) and anaerobes; used to treat osteomyelitis and MRSA; it has serious side-effects (e.g. antibiotic-associated colitis)

clindamycin

a semisynthetic bacteriostatic antibiotic derivative of lincomycin with improved activity against anaerobic bacteria. It also has some antiprotozoal activity.
References in periodicals archive ?
Subjects applied the OTC benzoyl peroxide with lipohydroxy acid or the prescription benzoyl peroxide and clindamycin twice daily for 12 weeks.
Patients with a recent history of systemic or topical clindamycin or erythromycin use are more likely to have pre-existing and anti-microbial resistant Propionibacterium acnes and commensal flora.
Key words: clindamycin, pharmacokinetics, treatment, avian, rock pigeon, Columba livia
Chloramphenicol, piperacillin-tazobactam, ertapenem and amoxicillin-clavulanate demonstrated the highest activity against these isolates, while 11% and 18% demonstrated resistance to metronidazole and clindamycin, respectively.
All 24 of the epidemic strain isolates that were tested for susceptibility were resistant to levofloxacin, gatifloxacin, and moxifloxacin, while 19 of the 24 (79%) were also resistant to clindamycin.
The Phase III trials were of identical design evaluating the beneficial effect of Velac compared with each of the single active ingredients, clindamycin gel and tretinoin gel, and with the placebo gel on two primary efficacy endpoints: Lesion Count and Investigator's Static Global Assessment (ISGA).
Specific use of clindamycin, cephalosporins, fluoroquinolones, piperacillin-tazobactam, and any other antibiotic drugs was recorded.
Clindamycin targets Propionibacterium acnes and decreases inflammation, whereas topical tretinoin normalizes follicular keratinization.
Connetics is developing Extina(R), a foam formulation of the antifungal drug ketoconazole, Actiza(TM), a foam formulation of clindamycin for treating acne, and Velac(R) Gel, a combination of clindamycin and tretinoin for treating acne.
In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae.
Intravenous clindamycin therapy was as effective as but lower in cost than three other recommended antibiotic regimens for the treatment of mild to moderate aspiration pneumonia in elderly patients in a prospective, randomized study.
Among the posters featured are Phase III data from Extina(TM), ketoconazole foam, 2%, as a potential new treatment for seborrheic dermatitis; Phase III data from Actiza(TM), clindamycin phosphate foam, 1%; and a meta analysis of the European trials with Velac(R) Gel.